Selleck Chemical LLC Inbrx-105-A4023-1MG
Inbrx-105 is a recombinant humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB with potential checkpoint inhibitory immunostimulating and antineoplastic activities By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition potentially leading to reduced tumor growth INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo MW 101 9 KD